Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Kardigan said it completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, with 156 participants enrolled. It amended the protocol to assess the primary endpoint of aortic valve calcium at Week 48 instead, and the press release now puts topline data in the second half of 2027, which means a longer wait for shareholders.
156 participants enrolled in KATALYST-AV; baseline data from the first 139 were analyzed
Primary endpoint of aortic valve calcium moved to Week 48; an internal interim analysis is planned for Week 24
Press release gives topline data timing as second half of 2027, while the 8-K item text says second half of 2026
Investor webcast at the American Heart Association meeting on November 7, 2026, at 8:00 AM ET
Eton Pharmaceuticals reported preliminary results from a four-week, placebo-controlled pilot study of ET-700, its investigational zinc acetate formulation for Wilson disease, in healthy volunteers. ET-700 showed fewer treatment-related adverse events than GALZIN but reduced hepatic copper uptake by less (12% versus 46%), and the company plans additional study arms in 2027. The filing states the findings are preliminary and do not establish clinical efficacy in patients with Wilson disease.
Treatment-related adverse events: 1 of 12 ET-700 participants versus 8 of 12 GALZIN participants
Hepatic copper uptake decreased 12% with ET-700 and 46% with GALZIN; placebo rose 11%
Intention-to-treat analysis of 35 participants showed GALZIN had a greater effect than ET-700 (p=0.023)
Company plans additional study arms in 2027 evaluating faster-release formulations
Cullinan Therapeutics disclosed updated Phase 1 dose escalation data for CLN-049, an investigational FLT3xCD3 T cell engager, in relapsed or refractory AML or MDS, and will present it at the 68th ASH Annual Meeting in December 2026. The data show an objective response rate of 45% at the 12 µg/kg target dose and cytokine release syndrome reduced to 26% under a two step-up dosing regimen, but the complete remission rates were 19% to 21% and the data come from a small, early-stage trial.
Study enrolled 87 patients (76 AML, 11 MDS) across 13 cohorts as of the data cutoff.
At 12 µg/kg, the CRc rate was 21% (6/29 patients, 2 CR) and the ORR was 45%; at 6 µg/kg, the CRc rate was 19% (3/16) and the ORR was 25%.
With a two step-up regimen, CRS incidence fell to 26% (7/27 patients) from 36% (13/36), and ICANS was 6% (5/87).
On October 29, 2026, CervoMed announced two peer-reviewed publications on neflamapimod for dementia with Lewy bodies (DLB). The placebo-controlled RewinD-LB Phase 2b trial, published in Alzheimer's Research & Therapy, did not confirm the Phase 2a results on its primary outcome in the full patient population, though the company cites subgroup and biomarker findings it says support further development.
RewinD-LB trial (159 patients) did not confirm the Phase 2a AscenD-LB primary outcome, change in CDR-SB, in the full intention-to-treat population.
In patients without Alzheimer's co-pathology (pTau181 <23 pg/mL), the placebo-adjusted CDR-SB difference was −0.51 points (95% CI: −1.16 to 0.13).
Discontinuation due to adverse events was 2.5% with neflamapimod and 1.3% with placebo.
The company is focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB.
Digital Brands Group said on October 26, 2026 that it will keep its Nasdaq listing after a strategic review, and it will reassess a move to private ownership each month. It also raised its forecast for guaranteed cash flow from its government contract, which matters to shareholders because the filing gives the new forecast but no revenue, profit, or per-share results.
Company decided to maintain its public listing after a strategic review, with a rolling monthly assessment of a possible transition to a private entity
Guaranteed cash flow forecast for September 1 to December 31, 2026 raised 42% to $4.7 million, up from $3.3 million
Cash flow comes from a two-year, $165 million binding government contract
Filing reports early-stage investor interest but gives no transaction terms or amounts
Coherus Oncology said on October 28, 2026 that interim data from its TREGCHECK program showed a confirmed overall response rate of 75% (6 of 8 evaluable patients) in first-line esophageal squamous cell carcinoma (ESCC) with tagmokitug, toripalimab and chemotherapy. The company plans to expand enrollment in both first-line and second-line ESCC cohorts, but the sample sizes are small and the drug is investigational and not approved.
First-line ESCC: confirmed overall response rate of 75% (6/8) as of October 14, 2026, rising to 89% (8/9) after two additional partial responses were confirmed following the data cutoff
Second-line ESCC at the 700 mg dose: clinical benefit rate of 33.3% (2/6) and confirmed overall response rate of 16.7% (1/6)
Safety: among 120 patients on tagmokitug plus toripalimab, 40% had immune-related adverse events of any grade and 20% had Grade 3-5 events; no Grade 5 treatment-related adverse events were reported
Contango Silver & Gold reported an update on its 2026 field season in Alaska and British Columbia, in a press release furnished under Item 7.01. Kitsault drilling totaled 56,492 meters against 40,000 meters originally planned, and Johnson Tract infrastructure was completed ahead of schedule and under budget. The company also said Manh Choh unit cash costs for the third quarter are expected to be similar to second-quarter 2026 levels, and it is guiding to the lower end of its 2026 production guidance.
Kitsault: 56,492 meters drilled across 152 holes, versus 40,000 meters planned; drilling completed October 15, 2026, with assays pending over the next 2-3 months
Johnson Tract: 2.6-mile access road and portal lay down area completed ahead of schedule and under budget; a camp pad originally planned for 2027 was also completed
Manh Choh: third processing campaign ended September 24, 2026, earlier than planned due to rain and higher reagent use; Q3 unit cash costs expected similar to Q2-2026
Third-quarter 2026 financial results are scheduled for release in mid-November 2026
Longeveron reported updated ELPIS II Phase 2b results for laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary endpoint of change in right ventricular ejection fraction at Month 12, but a pre-specified secondary endpoint, major adverse cardiac events (MACE), reached statistical significance. The company plans to request an FDA meeting, and the results are scheduled for presentation at the AHA 2026 Scientific Sessions.
Primary endpoint not met: mean RVEF decreased 2.6 percentage points in the standard of care group and 3.3 points in the laromestrocel group, with no statistically significant difference (p=0.68).
MACE: 8 events in the standard of care arm versus 1 in the laromestrocel arm (P=0.043).
FDA previously advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.
Data selected for a late-breaking podium presentation at AHA 2026 Scientific Sessions on November 8, 2026, in Chicago.
Xencor said its current operating plans give it cash to fund research, development and operations into 2029. The company also released updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, reporting confirmed objective response rates of 30.0% to 45.5% across three dose levels. The data are early and come from small groups, and the filing reports high rates of grade 3 or higher adverse events.
Cash expected to fund R&D and operations into 2029, based on current operating plans.
Confirmed objective response rate: 30.0% at 100 μg/kg (n=30), 44.0% at 200 μg/kg (n=25), 45.5% at 400 μg/kg (n=11).
Grade 3 or higher treatment-emergent adverse events occurred in 82.4% of expansion-dose patients (n=68); one treatment discontinuation due to cytokine release syndrome was reported.
Full 400 μg/kg analysis expected during 1H 2027 (20+ patients); a potential registration-enabling study is planned to start in 2027.
Eikon Therapeutics presented updated and initial clinical data from its PARP1 and WRN helicase programs at the 2026 ESMO Congress on October 23, 2026, and issued a press release on the results. The filing reports objective response rates alongside frequent Grade 3 or higher adverse events, and it contains no financial results, so the effect on shareholders is mixed and depends on later development steps.
EIK1003 Cohort 1C with weekly paclitaxel: objective response rate 26.4% (14/53); Grade 3 or higher adverse events in 80.3% (49/61) of participants
EIK1003 monotherapy Cohort 1A: objective response rate 14.3% (7/49) among efficacy-evaluable participants, with data cutoff October 1, 2026
EIK1004 monotherapy: objective response rate 12.1% (7/58); Grade 3 or higher adverse events in 17.6% (12/68) of participants
Further EIK1003 Cohort 1D and EIK1004 docetaxel combination results are expected in the second half of 2027
Aardvark Therapeutics reported exploratory efficacy and safety data from its previously terminated Phase 3 HERO trial and open-label extension, which the company says are directionally consistent with continued development of ARD-101 for Prader-Willi syndrome. The company states the partial data are not sufficient to draw definitive conclusions, the HERO trial was stopped early, and the FDA has lifted the clinical hold, so the company plans to request an FDA meeting on a new Phase 3 design.
HERO trial was terminated early with 67 of 90 planned participants randomized; all efficacy data are considered exploratory
OLE participants who switched from placebo to ARD-101 had an observed average 6-point reduction in HQ-CT score
One Grade 4 cardiac serious adverse event occurred at 800 mg twice daily with pitolisant, which the FDA concurred is related to a drug-drug interaction
FDA lifted the clinical hold on October 22, 2026; the company expects to resume PWS clinical activities in 2027
Tango Therapeutics reported updated Phase 1/2 data for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors, with an 82% objective response rate in 22 efficacy-evaluable pancreatic cancer patients as of an August 20, 2026 data cutoff. The company also approved a strategic reprioritization on October 22, 2026, which includes reducing its workforce by approximately 14%, mostly in research, and deprioritizing novel target discovery. For shareholders, the data support a planned Phase 3 study, while the restructuring and the dose level 2 safety results add uncertainty.
Pancreatic cohort: 82% objective response rate (18 of 22), median PFS not yet reached, 9-month PFS rate of 88%, as of August 20, 2026
Dose level 2 (250 mg vopimetostat) was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 safety-evaluable patients
Planned global randomized Phase 3 in front-line MTAP-deleted pancreatic cancer expected to start in the first half of 2027; NSCLC monotherapy data now expected in January 2027
Board approved reprioritization on October 22, 2026; approximately 14% workforce reduction, mostly in the research group
AIB Data Centers furnished an October 2026 investor presentation under Form 8-K Item 7.01, which highlights a 12-year agreement for 50 MW of critical IT capacity at its CLT1 site. The presentation also shows Q2 2026 revenue fell to $2.9 million from $4.7 million a year earlier, as the legacy hosting business was de-energized on June 5, 2026, and net loss widened to $3.5 million.
Customer agreement: 50 MW of critical IT capacity at CLT1 under a 12-year initial term with two five-year renewal options
Q2 2026 revenue of $2.9 million versus $4.7 million in Q2 2025; legacy hosting site de-energized June 5, 2026
Q2 2026 net loss of $3.5 million, or $0.07 per share, versus a net loss of $542 thousand, or $0.01 per share, in Q2 2025
Estimated first delivery of two 25 MW data halls at CLT1 in Q4 2027, which the company says is not a target or guidance
Coya Therapeutics plans to start an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS in November 2026, in response to requests from investigators and participants. To prioritize the ALS program, the company now expects its Phase 2 trial of COYA 302 in frontotemporal dementia to start in 2027 rather than the second half of 2026, while its cash runway guidance is unchanged.
Open-label extension expected to begin in November 2026, as the first cohort completes the 48-week treatment period
Phase 2 trial in frontotemporal dementia now expected in 2027, previously anticipated in the second half of 2026
Cash resources expected to fund operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout
ALSTARS trial to randomize approximately 120 subjects; primary endpoint is change in ALSFRS-R total score at Week 24 versus placebo
On October 13, 2026, Biomea Fusion reported topline Phase 1 GLP-131 results for BMF-650, its investigational oral GLP-1 receptor agonist. In Cohorts 1-4, mean Day 29 weight reduction ranged from 1.5% to 3.2% versus 0.1% for pooled placebo, and the company reported no severe or serious adverse events among active-dose participants, but the results are preliminary, the sample sizes are small, and the company says longer-term toxicology studies are still needed before further development, which may include a partnership.
Cohorts 1-4 (outpatient): mean Day 29 weight reduction of 1.5% to 3.2% versus 0.1% for pooled placebo.
Cohort 5 (under confinement, 200 mg then 400 mg): 6.1% (6.2 kg) mean weight reduction at Day 29; the company says it should be interpreted separately because confinement appeared to affect eating behavior.
No severe or serious TEAEs, TEAE-related dose modifications, or TEAE-related discontinuations across the 40 active-dose MAD participants; nausea occurred in 17.5% and vomiting in 7.5% across active cohorts.
Longer-term toxicology studies are required; the company is positioning BMF-650 for a strategic partnership, which could include licensing, while its primary focus remains icovamenib.
Seven Hills Realty Trust (SEVN) reported it closed two first mortgage loans totaling $98.0 million and received $68.0 million from two loan repayments, reducing office exposure to about 13% of its portfolio as of September 30, 2026. One repayment, a Dallas office loan, was settled at a $1.5 million discount to its $44.2 million balance, which the company said was well below its $6.3 million CECL reserve.
Two new first mortgage loans totaling $98.0 million: $68.0 million in Chattanooga, Tennessee and $30.0 million in Charlotte, North Carolina
Dallas office loan repaid at about 97% of its $44.2 million balance, a $1.5 million discount; the company said it was well below the $6.3 million CECL reserve as of June 30, 2026
Three loans in diligence totaling $121.7 million expected to close in the fourth quarter of 2026, subject to closing conditions
Third quarter 2026 earnings conference call scheduled for October 28, 2026 at 11:00 a.m. Eastern Time
In a September 28, 2026 press release, Sable Offshore said it plans to accelerate 4 additional Perforation Addition operations on Platform Hondo, bringing completed operations to 9 of 15 production wells before the expected Q4 2026 restart, up from 5 previously expected. The company estimated July and August oil sales at approximately 32 thousand gross barrels per day and expects September at approximately 34 thousand, while noting third-party sales constraints in late August and September.
Platform Hondo reconstruction and internal commissioning are complete; the MMA's final review of the instrumentation, control, and safety submission is expected in October 2026.
Completed Perf Adds before restart are now expected on 9 of 15 wells, versus 5 previously; each is estimated to add about 600 barrels of oil per day at about $800,000 per operation.
July and August oil sales were approximately 32 thousand gross barrels per day; September is expected at approximately 34 thousand.
October nominations to the crude purchaser are expected to average 38 thousand gross barrels per day, with an estimated exit rate of about 45 thousand before Hondo volumes are added.
Core Molding Technologies furnished slides from its September 28, 2026 investor day under Item 7.01, with the presentation attached as Exhibit 99.1 and posted on its website. The slides show trailing-twelve-month revenue fell from $377 million in 2022 to $254 million through the second quarter of 2026, while the company says its adjusted EBITDA margin improved from 8.7% in 2025 to 11.2%, which it presents as the result of its operating turnaround.
Trailing-twelve-month revenue of $254 million through Q2 2026, versus $274 million in 2025 and $377 million in 2022 per the slides
Adjusted EBITDA margin improved from 8.7% in 2025 to 11.2% per the slides; adjusted EBITDA is a non-GAAP measure
Slides cite $89 million of incremental annual revenue from new wins over 18 months and $210 million of annual revenue in active quotes
CEO Eric Palomaki and CFO Alex Panda are among presenters; the company says it aims to reach $500 million in revenue through economies of scale
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138 in patients with advanced solid tumors, using a September 1, 2026 data cutoff. Ten of 14 efficacy-evaluable patients achieved stable disease, and no dose-limiting toxicities were reported, but the sample is small and disease control was lower at Cycle 6 (35.7%) than at Cycle 3 (57.1%). The filing contains no financial results, so the update bears on the drug's clinical prospects rather than on current financials.
10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response at the September 1, 2026 data cutoff.
Disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
No dose-limiting toxicities were reported, including at the highest evaluated dose of 4.8 mg/kg, with 98 doses administered.
Post-hoc analysis found 6 of 15 evaluable patients (40%) with a growth modulation index above 1.3; the company said biomarker findings are hypothesis-generating.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.